临床试验

Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)

NCT：NCT05934526 · COMPLETED

NCT编号NCT05934526

状态COMPLETED

开始日期2023-12-28

完成时间2025-12-22

SponsorGB002, Inc. (INDUSTRY)

First posted2023-07-07

Last updated2026-05-19

简要摘要

The primary objective of the study is to determine the effect of seralutinib on improving exercise capacity in subjects with WHO Group 1 PAH who are FC II or III. The secondary objective for this trial is to determine time to clinical worsening.

官方来源

在 ClinicalTrials.gov 上查看 →

数据来自 ClinicalTrials.gov API。有关最新状态，请参阅官方记录。